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A B S T R A C T
Purpose: To illustrate a case of ocular infarction following percutaneous ethanol sclerotherapy of an orbital
arteriovenous malformation.
Observations: The patient is a 31-year-old female who developed ocular infarction of the left eye with light
perception vision, proptosis, ophthalmoplegia, and a cherry red spot following sclerotherapy of an orbital ar-
teriovenous malformation. Fluorescein angiography demonstrated decreased arteriolar filling with vascular
leakage, indocyanine green angiography showed decreased choroidal perfusion, and optical coherence tomo-
graphy revealed full thickness retinal edema. Magnetic resonance angiography and venography were negative
for venous sinus thrombosis or intracranial vascular compromise.
Conclusions and Importance: Ocular infarction is a rare and devastating disorder that may result in permanent
vision loss. Ethanol sclerotherapy has been reported to be effective in treating arteriovenous malformations. To
the best of our knowledge, this is the first report in the literature of ocular infarction following percutaneous
ethanol sclerotherapy to highlight this disease with multimodal imaging.
1. Introduction
Arteriovenous malformations (AVMs) are abnormal feeding blood
vessels which form a nidus that drains directly into the venous system
without any intervening capillaries. AVMs are rare, with AVMs invol-
ving the orbit or the periorbital region being even less frequent.1 AVMs
can present anywhere in the orbit or the periorbital region with com-
plex anatomical considerations in both their clinical presentation and
treatment. Symptomatic orbital AVMs can present as a periocular mass,
periocular edema, pulsation or bruit, proptosis, episcleral congestion,
elevated intraocular pressure (IOP), pain, decreased vision, reduced
extraocular motility, and diplopia.1 Management of orbital and peri-
orbital AVMs often requires multidisciplinary approach including em-
bolization, surgical resection, and preoperative embolization with sur-
gical resection.2,3 Long-term results showed AVM recurrence rates of
81% after surgical resection (with or without embolization), and 98%
with embolization alone.4
Ethanol sclerotherapy is among the treatment modalities used to
address vascular malformations. Ethanol is unique in that it perma-
nently destroys endothelial cells, and thus the nidus.5 Traditionally, the
use of sclerosants has been reserved for low-flow malformations.6
However, high-flow AVMs with a percutaneously accessible nidus
treated with ethanol sclerotherapy have been reported to have a ≥50%
reduction in size in about 50% of patient with lower permanent com-
plication rates compared to surgical excision with embolization.7 Pek-
kola et al. reported cures in 11 out of 19 patients treated with ethanol
sclerotherapy with low recurrence and complication rates, but did
comment on periorbital AVMs having more complications (e.g. tem-
porary Horner's syndrome, and severe epistaxis).8
Ocular infarction (OI) is infarction of intraocular structures, in-
cluding the retina and choroid. Recognizing the etiologies and clinical
symptoms of OI is important, but the prognosis is notably poor in many
cases. The goal of this report is to illustrate a case of OI after percuta-
neous ethanol sclerotherapy of an orbital AVM.
1.1. Case report
A 31-year-old female with a history of left medial orbital and nasal
AVM presented to an outside practice for AVM sclerotherapy. The AVM
was noted to be primarily supplied by the bilateral ophthalmic arteries
and left internal maxillary artery on preoperative arteriogram. A total
of 14mL of ethanol was reportedly used to thrombose the left orbit
AVM compartments percutaneously. The patient was noted to have
intact vasculature on immediate postoperative arteriogram. However,
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significant postoperative swelling developed resulting in the patient
being unable to open her left eye. Once she could open her eye on
postoperative day 4, she reported significant vision loss, and presented
to an outside hospital. Due to orbital edema, proptosis, decreased vi-
sion, and an intraocular pressure of 30 mmHg, the patient underwent
lateral canthotomy and cantholysis to relieve suspected orbital com-
partment syndrome. Patient was then transferred to us for further
management on postoperative day 5.
On arrival, exam of the left eye showed visual acuity of light per-
ception, positive left afferent pupillary defect, IOP of 21 mmHg, visual
field deficit to count fingers in all quadrants, and motility deficit of −2
in abduction, adduction, infraduction and −4 in supraduction. There
was upper and lower lid edema, periorbital ecchymosis, proptosis, and
chemosis. Patient's cornea, anterior chamber, iris and lens were un-
remarkable. On dilated fundus exam a pale retina with a cherry red spot
and no cilioretinal artery were apparent. The right eye had an un-
remarkable exam. Cranial nerve exam for V, VII, VIII, IX, X, XI, and XII
were unremarkable. Patient was admitted to the hospital for further
work-up to rule-out cavernous sinus thrombosis, orbital apex syndrome,
carotid-cavernous fistula, and other vascular compromise.
Urgent CT angiogram (CTA) revealed possible decreased contrast
filling of the left superior ophthalmic vein and the left cavernous sinus
compared to the right. This was suspicious for decreased flow or
thrombosis. Further evaluation with MR angiography and venography
(MRA/MRV) revealed a symmetric and unremarkable cavernous sinus,
and widely patent major dural venous sinuses with no filling defect to
suggest thrombosis. Patient was subsequently discharged and followed
closely as an outpatient.
On day 6 after AVM repair, the patient was seen in clinic for further
evaluation. Left eye clinical exam was unchanged except for a mild
decrease in orbital swelling. Fundus photos demonstrated an indistinct
optic disc, arteriolar attenuation and segmental filling, diffuse patchy
retinal whitening, retinal edema, and a cherry red spot (Fig. 1A). Op-
tical coherence tomography (OCT) macula revealed diffuse retinal
thickening with intraretinal cystic spaces (Fig. 3A). Early phase fluor-
escein angiography (FA) revealed poor retinal vascular filling with a
leading arterial edge of dye (Fig. 2A), while indocyanine green angio-
graphy (ICGA) showed decreased choroidal perfusion (Fig. 2A). Late
phase FA revealed vasculitis and leakage of dye (Fig. 2B). Repeat eva-
luation 20 days later was remarkable for hand motion vision, improved
extraocular motility, decreased retinal thickening and areas of peripa-
pillary atrophy (Fig. 1B). OCT macula revealed decreased retinal
thickening consistent with retinal atrophy, and areas of choroidal
thinning (from 242 μm thickness on post injection day 6, to 81 μm
thickness at post injection day 25) corresponding to the areas of
decreased perfusion observed on ICGA (Fig. 3B).
2. Discussion
OI has previously been reported in the treatment of orbital and
temporal lobe AVMs with polyvinyl alcohol, and in the treatment of
prominent facial veins with sodium tetradecyl sulphate,.9–11 However,
OI due to ethanol sclerotherapy has not been reported before, this case
highlights the disease with multimodal imagining including fundus
photos, OCT, and FA. On the other hand, orbital infarction defined as
infarction of both orbital and intraocular structures, has been reported
to occur due to sclerotherapy with sodium tetradecyl sulphate injected
percutaneously into a facial low-flow venous malformation without
orbital involvement, CTA in that case showed absent contrast en-
hancement of the ophthalmic artery and vein, suggesting thrombosis as
an explanation for the cause of orbital infarction,12. In our case, MRA/
MRV on post injection day 5 showed patent orbital vasculature.
Retrograde flow of ethanol into the ophthalmic artery is suspected
to be the cause of OI in our patient. This is supported by evidence of
intraocular ischemia on exam and multimodal imaging, in addition to
the retrieved arteriogram before and after sclerotherapy showing a
sclerotic ophthalmic artery (Fig. 4 A & B). Inadvertent injection of
ethanol directly into the orbit or the globe may produce a similar result
as ethanol has been shown to be cytotoxic and induce vasospasm.13
However, this is less likely as the dilated fundus exam was negative for
any puncture wounds, the procedure was done under direct interven-
tional radiology guidance, and the vasculitis seen on the fluorescein
angiography is more consistent with retrograde flow of ethanol rather
than vasospasm (Fig. 2B). Unfortunately, due to the patient's significant
eyelid edema postoperatively, the timing of the patient's vision loss
remains uncertain.
This case demonstrates the complex nature of orbital AVMs, and
while ethanol sclerotherapy can be an effective treatment option, it may
be associated with serious complications.8,14 Patients should be made
aware of irreversible vision loss and injury to the orbital structures as
part of obtaining an informed consent. Furthermore, physicians
managing AVMs of the orbital region should consider a multi-
disciplinary approach including a facial/orbital surgeon, interventional
radiologist, and an ophthalmologist.
3. Conclusions
To the best of our knowledge this is the first reported case of OI after
percutaneous ethanol embolization of an orbital AVM. In addition, this
is the first report in the literature to highlight clinical retinal and
Fig. 1. Color fundus photos at six days (A) and
twenty-five days post sclerotherapy (B). A)
Fundus photos demonstrate indistinct optic nerve
margins, arteriolar attenuation, diffuse patchy ret-
inal whitening, retinal edema, and a cherry red spot
(OS) vs. normal fundus (OD) at six days post scler-
otherapy. B) Fundus photos demonstrate disc pallor,
peripapillary atrophy, marked attenuation and ob-
literation of arterioles, residual macular edema, tes-
sellated fundus appearance, and inferior coarse
hyper pigmentation (OS) vs. normal fundus (OD) at
twenty-five days post sclerotherapy. (For interpreta-
tion of the references to colour in this figure legend,
the reader is referred to the Web version of this ar-
ticle.)
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Fig. 2. Early phase fluorescein/in-
docyanine green angiography (A) and
late phase fluorescein/indocyanine
green angiography six days post scler-
otherapy (B). A) Fluorescein angiography
(FA) shows retinal hypofluorescence, seg-
mental arteriolar hyperfluorescence, and
delayed arteriolar fluorescein perfusion at
48 s, and indocyanine green angiography
(ICGA) shows decreased choroidal perfusion
(OS) vs. unremarkable angiography at 1min
and 16 s (OD). B) FA shows persistent ar-
teriolar hypofluorescence and vasculitis at
5 min and 17 s, and ICGA shows persistent
decreased choroidal perfusion (OS) vs un-
remarkable angiography at 4min 55 s (OD).
Fig. 3. Optical coherence tomography six
days post sclerotherapy (A) and twenty-
five days post sclerotherapy (B). A)
Optical coherence tomography (OCT) de-
monstrating full-thickness retinal thick-
ening, hyperreflectivity, disruption of fo-
veal contour, outer retinal hyporeflectivity
(OS), and choroidal thickness of (242 μm)
vs. preserved foveal contour with dis-
tinguished retinal layers (OD) and choroidal
thickness of (232 μm) at six days post
sclerotherapy. B) OCT demonstrating per-
sistent retinal thickening, irregularity, in-
traretinal cystic spaces, and thinning of the
choroid (choroidal thickness of (81 μm)
(OS) vs. unremarkable retinal scan (OD)
with choroidal thickness of (213 μm) at
twenty-five days post sclerotherapy.
Fig. 4. Angiography of the left arter-
iovenous malformation pre-embolization
& post-embolization. A) Pre-embolization
arteriography of the left internal carotid
artery demonstrates a lateral view of the
orbital arteriovenous malformation supplied
by the left ophthalmic artery (arrow). B)
Post-embolization arteriography of the left
internal carotid artery demonstrates de-
creased thickness of the left ophthalmic ar-
tery (arrow) without evidence of the arter-
iovenous malformation.
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choroidal findings on multimodal imaging.
As novel therapies and innovative techniques are introduced in the
management of orbital AVMs, the awareness of the potential compli-
cations, such as OI, becomes even more important. As such, close col-
laboration with an ophthalmologist or a professional experienced in the
presentation and treatment of ocular pathology is essential.
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